US · Healthcare · Biotechnology
EPS came in at -0.91 against a street estimate of -0.80 — a miss of 13.7%.
with an average price target of $41.49.
| Fund | Stake |
|---|---|
| VR Adviser, LLC | 5.27% |
| Orbimed Advisors LLC | 5.25% |
| Adage Capital Partners Gp LLC | 4.19% |
| Millennium Management LLC | 3.60% |
| Rosalind Advisors, Inc. | 2.10% |
| DCF Advisers, LLC | 1.96% |
| Sio Capital Management, LLC | 1.78% |
| Morgan Stanley - Brokerage Accounts | 1.40% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Cybin Inc. Common Stock — free to start.
Google PlayApp StoreData updated 2026-09-18.